☰

Nathalie Le Bastard, Ph.D. - Publications

Affiliations: 
2011 Universiteit Antwerpen (Belgium) 
Area:
Neuroscience Biology, General
Tree Info Grants Similar researchers PubMed Report error

51 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Silva-Spínola A, Leitão MJ, Nadal A, Le Bastard N, Santana I, Baldeiras I. Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology. Alzheimer's Research & Therapy. 16: 51. PMID 38454502 DOI: 10.1186/s13195-024-01397-9  0.524
2022 Wilson EN, Young CB, Ramos Benitez J, Swarovski MS, Feinstein I, Vandijck M, Le Guen Y, Kasireddy NM, Shahid M, Corso NK, Wang Q, Kennedy G, Trelle AN, Lind B, Channappa D, ... ... Le Bastard N, et al. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease. Alzheimer's Research & Therapy. 14: 172. PMID 36371232 DOI: 10.1186/s13195-022-01116-2  0.487
2021 Gobom J, Parnetti L, Rosa-Neto P, Vyhnalek M, Gauthier S, Cataldi S, Lerch O, Laczo J, Cechova K, Clarin M, Benet AI, Pascoal TA, Rahmouni N, Vandijck M, Huyck E, ... Le Bastard N, et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine. PMID 34773730 DOI: 10.1515/cclm-2021-0651  0.486
2019 Leitão MJ, Silva-Spínola A, Santana I, Olmedo V, Nadal A, Le Bastard N, Baldeiras I. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease. Alzheimer's Research & Therapy. 11: 91. PMID 31759396 DOI: 10.1186/s13195-019-0550-8  0.434
2019 Alcolea D, Pegueroles J, Muñoz L, Camacho V, López-Mora D, Fernández-León A, Le Bastard N, Huyck E, Nadal A, Olmedo V, Sampedro F, Montal V, Vilaplana E, Clarimón J, Blesa R, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. Annals of Clinical and Translational Neurology. PMID 31464088 DOI: 10.1002/acn3.50873  0.304
2019 Delaby C, Muñoz L, Torres S, Nadal A, Le Bastard N, Lehmann S, Lleó A, Alcolea D. Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. Clinica Chimica Acta; International Journal of Clinical Chemistry. 490: 98-101. PMID 30579960 DOI: 10.1016/j.cca.2018.12.021  0.406
2018 Niemantsverdriet E, Feyen BFE, Le Bastard N, Martin JJ, Goeman J, De Deyn PP, Bjerke M, Engelborghs S. Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort. Journal of Alzheimer's Disease : Jad. PMID 29614653 DOI: 10.3233/Jad-170927  0.571
2015 Le Bastard N, De Deyn PP, Engelborghs S. Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clinical Chemistry. 61: 734-43. PMID 25869575 DOI: 10.1373/Clinchem.2014.236679  0.529
2015 Niemantsverdriet E, Feyen BF, Le Bastard N, Martin JJ, Goeman J, De Deyn PP, Engelborghs S. Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up. Journal of Alzheimer's Disease : Jad. 45: 1039-43. PMID 25633672 DOI: 10.3233/Jad-142103  0.562
2015 Van der Mussele S, Le Bastard N, Saerens J, Somers N, Mariën P, Goeman J, De Deyn PP, Engelborghs S. Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia. Aging & Mental Health. 19: 247-57. PMID 24962058 DOI: 10.1080/13607863.2014.924900  0.584
2014 Slaets S, Vanmechelen E, Le Bastard N, Decraemer H, Vandijck M, Martin JJ, De Deyn PP, Engelborghs S. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: S290-8. PMID 24439167 DOI: 10.1016/J.Jalz.2013.10.004  0.606
2013 Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP, Engelborghs S. Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. Journal of Alzheimer's Disease : Jad. 36: 759-67. PMID 23666174 DOI: 10.3233/Jad-130107  0.613
2013 Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP, Engelborghs S. Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. Journal of Alzheimer's Disease : Jad. 36: 759-67. PMID 23666174 DOI: 10.3233/JAD-130107  0.51
2013 Slaets S, Le Bastard N, Theuns J, Sleegers K, Verstraeten A, De Leenheir E, Luyckx J, Martin JJ, Van Broeckhoven C, Engelborghs S. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies. Journal of Alzheimer's Disease : Jad. 35: 137-46. PMID 23364139 DOI: 10.3233/Jad-122176  0.564
2013 Engelborghs S, Sleegers K, Van der Mussele S, Le Bastard N, Brouwers N, Van Broeckhoven C, De Deyn PP. Brain-specific tryptophan hydroxylase, TPH2, and 5-HTTLPR are associated with frontal lobe symptoms in Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 35: 67-73. PMID 23334703 DOI: 10.3233/Jad-101305  0.568
2013 Engelborghs S, Sleegers K, Van der Mussele S, Le Bastard N, Brouwers N, Van Broeckhoven C, De Deyn PP. Brain-specific tryptophan hydroxylase, TPH2, and 5-HTTLPR are associated with frontal lobe symptoms in Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 35: 67-73. PMID 23334703 DOI: 10.3233/JAD-101305  0.446
2013 Van der Mussele S, Bekelaar K, Le Bastard N, Vermeiren Y, Saerens J, Somers N, Mariën P, Goeman J, De Deyn PP, Engelborghs S. Prevalence and associated behavioral symptoms of depression in mild cognitive impairment and dementia due to Alzheimer's disease. International Journal of Geriatric Psychiatry. 28: 947-58. PMID 23255479 DOI: 10.1002/Gps.3909  0.581
2013 Van der Mussele S, Bekelaar K, Le Bastard N, Vermeiren Y, Saerens J, Somers N, Mariën P, Goeman J, De Deyn PP, Engelborghs S. Prevalence and associated behavioral symptoms of depression in mild cognitive impairment and dementia due to Alzheimer's disease. International Journal of Geriatric Psychiatry. 28: 947-58. PMID 23255479 DOI: 10.1002/gps.3909  0.465
2013 Vermeiren Y, Le Bastard N, Van Hemelrijck A, Drinkenburg WH, Engelborghs S, De Deyn PP. Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 488-98. PMID 23159046 DOI: 10.1016/j.jalz.2012.06.010  0.36
2013 Vermeiren Y, Le Bastard N, Van Hemelrijck A, Drinkenburg WH, Engelborghs S, De Deyn PP. Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 488-98. PMID 23159046 DOI: 10.1016/J.Jalz.2012.06.010  0.507
2013 Le Bastard N, Aerts L, Sleegers K, Martin JJ, Van Broeckhoven C, De Deyn PP, Engelborghs S. Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 33: 807-22. PMID 23034521 DOI: 10.3233/JAD-2012-110029  0.626
2013 Le Bastard N, Aerts L, Sleegers K, Martin JJ, Van Broeckhoven C, De Deyn PP, Engelborghs S. Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 33: 807-22. PMID 23034521 DOI: 10.3233/JAD-2012-110029  0.528
2013 Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. Journal of Alzheimer's Disease : Jad. 33: 117-31. PMID 22936010 DOI: 10.3233/Jad-2012-121246  0.564
2013 Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. Journal of Alzheimer's Disease : Jad. 33: 117-31. PMID 22936010 DOI: 10.3233/JAD-2012-121246  0.564
2013 Van der Mussele S, Le Bastard N, Vermeiren Y, Saerens J, Somers N, Mariën P, Goeman J, De Deyn PP, Engelborghs S. Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults. International Journal of Geriatric Psychiatry. 28: 265-75. PMID 22549770 DOI: 10.1002/Gps.3820  0.552
2013 Van der Mussele S, Le Bastard N, Vermeiren Y, Saerens J, Somers N, Mariën P, Goeman J, De Deyn PP, Engelborghs S. Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults. International Journal of Geriatric Psychiatry. 28: 265-75. PMID 22549770 DOI: 10.1002/gps.3820  0.423
2012 Engelborghs S, Le Bastard N. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. Journal of the Neurological Sciences. 322: 197-9. PMID 22947896 DOI: 10.1016/J.Jns.2012.08.003  0.575
2012 Engelborghs S, Le Bastard N. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. Journal of the Neurological Sciences. 322: 197-9. PMID 22947896 DOI: 10.1016/j.jns.2012.08.003  0.575
2012 del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, Sáez-Valero J, Saka E, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine. 6: 419-30. PMID 22917144 DOI: 10.2217/Bmm.12.46  0.422
2012 Engelborghs S, Le Bastard N. The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. Molecular Diagnosis & Therapy. 16: 135-41. PMID 22646065 DOI: 10.2165/11634170-000000000-00000  0.57
2012 Engelborghs S, Le Bastard N. The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. Molecular Diagnosis & Therapy. 16: 135-41. PMID 22646065 DOI: 10.1007/Bf03262201  0.57
2012 Bettens K, Brouwers N, Engelborghs S, Lambert JC, Rogaeva E, Vandenberghe R, Le Bastard N, Pasquier F, Vermeulen S, Van Dongen J, Mattheijssens M, Peeters K, Mayeux R, St George-Hyslop P, Amouyel P, et al. Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Molecular Neurodegeneration. 7: 3. PMID 22248099 DOI: 10.1186/1750-1326-7-3  0.458
2012 Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 8: 65-73. PMID 22047631 DOI: 10.1016/J.Jalz.2011.07.004  0.456
2011 Vermeiren Y, Le Bastard N, Clark CM, Engelborghs S, De Deyn PP. Serum glutamine synthetase has no value as a diagnostic biomarker for Alzheimer's disease. Neurochemical Research. 36: 1858-62. PMID 21597934 DOI: 10.1007/s11064-011-0504-4  0.569
2011 Vermeiren Y, Le Bastard N, Clark CM, Engelborghs S, De Deyn PP. Serum glutamine synthetase has no value as a diagnostic biomarker for Alzheimer's disease. Neurochemical Research. 36: 1858-62. PMID 21597934 DOI: 10.1007/s11064-011-0504-4  0.448
2010 Aries MJ, Le Bastard N, Debruyne H, Van Buggenhout M, Nagels G, De Deyn PP, Engelborghs S. Relation between frontal lobe symptoms and dementia severity within and across diagnostic dementia categories. International Journal of Geriatric Psychiatry. 25: 1186-95. PMID 20957694 DOI: 10.1002/Gps.2481  0.528
2010 Chen CC, Engelborghs S, Dewaele S, Le Bastard N, Martin JJ, Vanhooren V, Libert C, De Deyn PP. Altered serum glycomics in Alzheimer disease: a potential blood biomarker? Rejuvenation Research. 13: 439-44. PMID 20426627 DOI: 10.1089/Rej.2009.0992  0.633
2010 Chen CC, Engelborghs S, Dewaele S, Le Bastard N, Martin JJ, Vanhooren V, Libert C, De Deyn PP. Altered serum glycomics in Alzheimer disease: a potential blood biomarker? Rejuvenation Research. 13: 439-44. PMID 20426627 DOI: 10.1089/rej.2009.0992  0.539
2010 Le Bastard N, Leurs J, Blomme W, De Deyn PP, Engelborghs S. Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients. Journal of Alzheimer's Disease : Jad. 21: 291-301. PMID 20421698 DOI: 10.3233/Jad-2010-091501  0.613
2010 Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiology of Aging. 31: 1867-76. PMID 19150153 DOI: 10.1016/j.neurobiolaging.2008.10.017  0.561
2010 Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiology of Aging. 31: 1867-76. PMID 19150153 DOI: 10.1016/J.Neurobiolaging.2008.10.017  0.649
2009 Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S. No correlation between time-linked plasma and CSF Abeta levels. Neurochemistry International. 55: 820-5. PMID 19695299 DOI: 10.1016/j.neuint.2009.08.006  0.378
2009 Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S. No correlation between time-linked plasma and CSF Abeta levels. Neurochemistry International. 55: 820-5. PMID 19695299 DOI: 10.1016/j.neuint.2009.08.006  0.52
2009 Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochemistry International. 55: 214-8. PMID 19524111 DOI: 10.1016/J.Neuint.2009.02.017  0.638
2009 Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochemistry International. 55: 214-8. PMID 19524111 DOI: 10.1016/j.neuint.2009.02.017  0.545
2009 Debruyne H, Van Buggenhout M, Le Bastard N, Aries M, Audenaert K, De Deyn PP, Engelborghs S. Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment? International Journal of Geriatric Psychiatry. 24: 556-62. PMID 19132643 DOI: 10.1002/Gps.2154  0.412
2008 Aries MJ, Debruyne H, Engelborghs S, Le Bastard N, Somers N, Gorissen D, Pickut BA, De Deyn PP. Reversal of head drop after discontinuation of olanzapine in a DLB patient. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 1760-2. PMID 18661562 DOI: 10.1002/Mds.22182  0.382
2008 Engelborghs S, Vloeberghs E, Le Bastard N, Van Buggenhout M, Mariën P, Somers N, Nagels G, Pickut BA, De Deyn PP. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochemistry International. 52: 1052-60. PMID 18093695 DOI: 10.1016/j.neuint.2007.10.018  0.442
2008 Engelborghs S, Vloeberghs E, Le Bastard N, Van Buggenhout M, Mariën P, Somers N, Nagels G, Pickut BA, De Deyn PP. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochemistry International. 52: 1052-60. PMID 18093695 DOI: 10.1016/J.Neuint.2007.10.018  0.565
2007 Le Bastard N, Van Buggenhout M, De Leenheir E, Martin JJ, De Deyn PP, Engelborghs S. LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. 62: 923-4; author reply . PMID 17702886 DOI: 10.1093/Gerona/62.8.923  0.56
2007 Le Bastard N, Van Buggenhout M, De Leenheir E, Martin JJ, De Deyn PP, Engelborghs S. LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. 62: 923-4; author reply . PMID 17702886  0.435
Show low-probability matches.